1379573-92-8

1379573-92-8 structure

Name: CBB1007
Chemical Name: Methyl 3-{[4-(4-carbamimidoylbenzoyl)-1-piperazinyl]carbonyl}-5-[(4-carbamimidoyl-1-piperazinyl)methyl]benzoate
CAS Number: 1379573-92-8
Molecular Formula: C₂₇H₃₄N₈O₄
Molecular Weight: 534.610
Catalog: Signaling Pathways Epigenetics Histone Demethylase
Create Date: 2018-02-07 21:40:52
Modify Date: 2024-01-12 10:48:32
CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).IC50 Value: 5.27 uMTarget: hLSD1CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 μM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 μM). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM).

Name	Methyl 3-{[4-(4-carbamimidoylbenzoyl)-1-piperazinyl]carbonyl}-5-[(4-carbamimidoyl-1-piperazinyl)methyl]benzoate
Synonyms	Methyl 3-{[4-(4-carbamimidoylbenzoyl)-1-piperazinyl]carbonyl}-5-[(4-carbamimidoyl-1-piperazinyl)methyl]benzoate Benzoic acid, 3-[[4-[4-(aminoiminomethyl)benzoyl]-1-piperazinyl]carbonyl]-5-[[4-(aminoiminomethyl)-1-piperazinyl]methyl]-, methyl ester CBB1007

Description	CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).IC50 Value: 5.27 uMTarget: hLSD1CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 μM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 μM). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM).
Related Catalog	Signaling Pathways >> Epigenetics >> Histone Demethylase Research Areas >> Cancer
References	[1]. Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011 Dec 1;71(23):7238-49.